By Riley Griffin
For the past three years, Eli Lilly & Co. has been quietly watching and investing in technologies that harness the messaging power of cells in hopes that it could lead to new medicines.
One-fifth of the company’s pipeline is composed of drug candidates that are based on nucleic acids like RNA or DNA, the information-carrying part of cells. While consumers have heard much about how messenger RNA in Covid-19 vaccines is used to prime the body to ward off infection, Lilly wants to use these new technologies to target cardiovascular and brain diseases.
“What seemed edgy a few years ago …
To read the full article log in.
Learn more about a Bloomberg Law subscription.
Mobile Point-of-Sale (mPOS) Terminals Market See Huge Growth for New Normal | Bixolon Co, Citizen Systems Europe GmbH, Dspread Technology – The Daily Vale – The Daily Vale
Your MediaYour Media“ Get Sample Report Buy Complete ReportNew Jersey, United States –The Mobile Point-of-Sale (mPOS) Terminals Market Research Report is a professional asset that